1.50
-0.16(-9.64%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.65 |
| Day High | 1.72 |
| Day Low | 1.49 |
| 52-Week High | 6.4 |
| 52-Week Low | 1.14 |
| Volume | 967,750 |
| Average Volume | 294,925 |
| Market Cap | 22.51M |
| PE | -1.11 |
| EPS | -1.35 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 1.67 |
| Change | -0.16 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $20.24 as of July 10, 2025 at a share price of $1.5. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $21.49 as of July 10, 2025 at a share price of $1.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
GlobeNewswire Inc.
Jul 08, 2025 1:15 PM GMT
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated
Longeveron® Appoints Than Powell as Chief Business Officer
GlobeNewswire Inc.
Jun 26, 2025 1:05 PM GMT
Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire Inc.
Jun 24, 2025 10:30 AM GMT
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submissio